Caribou Biosciences, Inc. (CRBU): Price and Financial Metrics
CRBU Price/Volume Stats
Current price | $1.42 | 52-week high | $8.33 |
Prev. close | $1.35 | 52-week low | $1.22 |
Day low | $1.33 | Volume | 1,655,700 |
Day high | $1.46 | Avg. volume | 1,450,177 |
50-day MA | $1.63 | Dividend yield | N/A |
200-day MA | $2.08 | Market Cap | 128.59M |
CRBU Stock Price Chart Interactive Chart >
Caribou Biosciences, Inc. (CRBU) Company Bio
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. Caribou Biosciences has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
CRBU Price Returns
1-mo | -7.19% |
3-mo | -27.55% |
6-mo | -32.06% |
1-year | N/A |
3-year | -85.80% |
5-year | N/A |
YTD | -10.69% |
2024 | -72.25% |
2023 | -8.76% |
2022 | -58.38% |
2021 | N/A |
2020 | N/A |
Loading social stream, please wait...